Dyspepsia and Gastro-Oesophageal Reflux Disease

Warning

NICE clinical guideline CG184 provides information on the investigation and management of gastro-oesophageal reflux disease (GORD) and dyspepsia in adults.

In most patients with GORD, adequate symptom control is the principal aim of treatment. Symptoms should be controlled by using the lowest dose of the most cost–effective agent (antacid, H2 receptor antagonist or proton pump inhibitor). An ‘on demand’ regimen is acceptable providing it is effective.

Preferred list (P)

CO-MAGALDROX (Mucogel® suspension)

 

Preferred list (P)

SODIUM ALGINATE WITH CALCIUM CARBONATE AND SODIUM BICARBONATE (Peptac® liquid) 

  • High in sodium and should be used with care when salt restriction is important (heart disease, hepatic or renal impairment).

Prescribing notes:

  • Gaviscon® and Gaviscon Advance® are NHSL non-formulary preparations.

To indicate the category of a formulary medicine, updated sections adopt the following key:

Preferred list (P): First-line formulary choices.

Total list (T): Alternative choices when preferred list options not effective/not tolerated, or not indicated.

Specialist initiation (S1): Specialist initiation, or on the advice of a Consultant or Specialist Practitioner in this therapeutic area. Continuation in primary care is acceptable.

Specialist use only (S2): Supply via hospital, Homecare Service or a hospital based prescription (HBP) for dispensing by community pharmacy. Not prescribed in primary care setting.

Editorial Information

Last reviewed: 31/01/2022

Next review date: 31/01/2025

Author(s): NHSL.

Version: Please refer to the introduction section for an explanation of the review dates above.

Approved By: ADTC

Reviewer name(s): ADTC.